a hrefhttps:www.fiercepharma.compharmaattruby-cruises-toward-blockbuster-land-bridgebio-ceo-spots-stabilizer-first-attr-market hreflangenAttruby cruises toward blockbuster land as BridgeBio CEO spots stabilizer-first ATTR marketa

Despite their divergent second-quarter performance against consensus estimates, BridgeBio and Alnylam are now targeting the same populationfirst-line ATTR-CM patientsas the silencer-vs-stabilizer debate drags on.